Gene Therapy Market by Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral)), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1             OBJECTIVES OF THE STUDY
1.2             MARKET DEFINITION
1.3             MARKET SCOPE
1.3.1              MARKETS COVERED.. 17
1.3.2              YEARS CONSIDERED FOR THE STUDY
1.4             CURRENCY
1.5             LIMITATIONS
1.6             STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1             RESEARCH DATA
2.2             SECONDARY DATA
2.2.1              SECONDARY SOURCES.. 20
2.3             PRIMARY DATA
2.4             MARKET SIZE ESTIMATION
2.4.1              BOTTOM-UP APPROACH
2.4.2              BOTTOM-UP APPROACH FOR THE NON-VIRAL VECTORS AND VIRAL
VECTORS MARKET
2.4.3              GROWTH FORECAST. 23
2.5             MARKET BREAKDOWN AND DATA TRIANGULATION
2.6             ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1             GENE THERAPY MARKET OVERVIEW
4.2             NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR (2018)
4.3             GEOGRAPHICAL SNAPSHOT OF THE GENE THERAPY MARKET

5.... MARKET OVERVIEW

5.1             INTRODUCTION
5.2             MARKET DYNAMICS
5.2.1              DRIVERS
5.2.1.1            HIGH INCIDENCE OF CANCER AND OTHER TARGET DISEASES
5.2.1.2            PRODUCT APPROVALS
5.2.1.3            FUNDING FOR GENE THERAPY RESEARCH

5.2.2              OPPORTUNITIES
5.2.2.1            STRONG PRODUCT PIPELINE
5.2.3              CHALLENGES
5.2.3.1            HIGH COST OF TREATMENTS

6.... GENE THERAPY MARKET, BY VECTOR

6.1             INTRODUCTION
6.2             NON-VIRAL VECTORS
6.2.1              OLIGONUCLEOTIDES.. 38
6.2.1.1            OLIGONUCLEOTIDES ACCOUNTED FOR THE LARGEST SHARE OF THE NON-VIRAL VECTORS MARKET
6.2.2              OTHER NON-VIRAL VECTORS
6.3             VIRAL VECTORS
6.3.1              RETROVIRAL VECTORS
6.3.1.1            GAMMA-RETROVIRAL VECTORS
6.3.1.1.1            AVAILABILITY OF A WIDE RANGE OF GAMMA-RETROVIRAL VECTORS SUPPORTING MARKET GROWTH
6.3.1.2            LENTIVIRAL VECTORS
6.3.1.2.1            NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE LENTIVIRAL VECTORS MARKET
6.3.2              ADENO-ASSOCIATED VIRUS VECTORS
6.3.2.1            POSSIBLE USE IN IN VIVO APPLICATIONS HAS DRIVEN INTEREST IN ADENO-ASSOCIATED VIRUS VECTORS
6.3.3              OTHER VIRAL VECTORS

7.... GENE THERAPY MARKET, BY INDICATION

7.1             INTRODUCTION
7.2             NEUROLOGICAL DISEASES
7.2.1              NEUROLOGICAL DISEASES FORM THE LARGEST INDICATION SEGMENT IN THIS MARKET
7.3             CANCER
7.3.1              DEMAND FOR GENE THERAPIES FOR THE TREATMENT OF CANCER TO GROW AT A HIGH RATE
7.4             HEPATOLOGICAL DISEASES
7.4.1              INCREASING PREVALENCE OF HEPATITIS B INFECTIONS WILL SUPPORT MARKET GROWTH
7.5             DUCHENNE MUSCULAR DYSTROPHY
7.5.1              RISING PREVALENCE OF DMD TO SUPPORT MARKET GROWTH
7.6             OTHER INDICATIONS

8.... GENE THERAPY MARKET, BY DELIVERY METHOD

8.1             INTRODUCTION
8.2             IN VIVO GENE THERAPY
8.2.1              IN VIVO GENE THERAPY SEGMENT TO DOMINATE THE MARKET
8.3             EX VIVO GENE THERAPY
8.3.1              EX VIVO GENE THERAPY SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD

9.... GENE THERAPY MARKET, BY REGION

9.1             INTRODUCTION
9.2             NORTH AMERICA
9.2.1              US
9.2.1.1            THE US DOMINATES THE GLOBAL GENE THERAPY MARKET
9.2.2              CANADA
9.2.2.1            GROWING BURDEN OF CANCER WILL SUPPORT MARKET GROWTH IN CANADA
9.3             EUROPE
9.3.1              GERMANY
9.3.1.1            GERMANY ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN EUROPE
9.3.2              FRANCE
9.3.2.1            INCREASING CANCER INCIDENCE TO SUPPORT MARKET GROWTH
9.3.3              UK
9.3.3.1            RISING INCIDENCE OF MELANOMA WILL SUPPORT MARKET GROWTH IN THE UK
9.3.4              ITALY
9.3.4.1            HIGH INCIDENCE OF TARGETED DISEASES AND INCREASING PER CAPITA HEALTHCARE SPENDING WILL DRIVE MARKET GROWTH IN ITALY
9.3.5              SPAIN
9.3.5.1            RISING CANCER INCIDENCE AND INCREASING HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH IN SPAIN
9.3.6              REST OF EUROPE
9.4             ASIA PACIFIC
9.4.1              JAPAN
9.4.1.1            JAPAN DOMINATES THE APAC MARKET FOR GENE THERAPY
9.4.2              CHINA
9.4.2.1            RISING PREVALENCE OF CANCER AND ESTABLISHED BASE FOR GENE THERAPY TO SUPPORT MARKET GROWTH IN CHINA
9.4.3              REST OF ASIA PACIFIC
9.5             REST OF THE WORLD

10.. COMPETITIVE LANDSCAPE

10.1          OVERVIEW
10.2          MARKET SHARE ANALYSIS, 2018
10.3          KEY STRATEGIES
10.4          COMPETITIVE LEADERSHIP MAPPING (2018). 93
10.4.1            VISIONARY LEADERS.. 93
10.4.2            INNOVATORS
10.4.3            DYNAMIC DIFFERENTIATORS
10.4.4            EMERGING COMPANIES

11.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS & MNM VIEW)*
11.1          BIOGEN
11.2          SAREPTA THERAPEUTICS
11.3          GILEAD SCIENCES, INC.
11.4          AMGEN, INC.
11.5          NOVARTIS AG
11.6          ORCHARD THERAPEUTICS PLC
11.7          SPARK THERAPEUTICS, INC. (A PART OF ‎F. HOFFMANN-LA ROCHE)
11.8          MOLMED S.P.A.
11.9          ANGES, INC.
11.10        BLUEBIRD BIO, INC.
11.11        JAZZ PHARMACEUTICALS PLC
11.12        DYNAVAX TECHNOLOGIES
11.13        HUMAN STEM CELLS INSTITUTE
11.14        SIBIONO GENETECH CO., LTD.
11.15        SHANGHAI SUNWAY BIOTECH CO., LTD.
11.16        UNIQURE N.V.
11.17        GENSIGHT BIOLOGICS S.A.
11.18        CELGENE CORPORATION (A BRISTOL-MYERS SQUIBB COMPANY)
11.19        CELLECTIS
11.20        SANGAMO THERAPEUTICS
11.21        MUSTANG BIO
11.22        AGTC (APPLIED GENETIC TECHNOLOGIES CORPORATION)
11.23        POSEIDA THERAPEUTICS, INC.
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS & MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
12.. APPENDIX

LIST OF TABLES

TABLE 1              GLOBAL CANCER INCIDENCE, 2018 VS. 2025
TABLE 2              PRODUCT APPROVALS, 2015–2019
TABLE 3              GENE THERAPY MARKET: LIST OF SOME PIPELINE DRUGS
TABLE 4              PRICE OF GENE THERAPY PRODUCTS, 2018
TABLE 5              GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 6              GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY REGION,
2017–2024 (USD MILLION)
TABLE 7              GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 8              GENE THERAPY MARKET FOR OLIGONUCLEOTIDES, BY REGION,
2017–2024 (USD MILLION)
TABLE 9              GENE THERAPY MARKET FOR OTHER NON-VIRAL VECTORS, BY REGION,
2017–2024 (USD MILLION)
TABLE 10            GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION,
2017–2024 (USD MILLION)
TABLE 11            GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 12            GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY REGION,
2017–2024 (USD MILLION)
TABLE 13            GENE THERAPY MARKET FOR RETROVIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 14            GENE THERAPY MARKET FOR GAMMA-RETROVIRAL VECTORS, BY REGION,
2017–2024 (USD MILLION)
TABLE 15            GENE THERAPY MARKET FOR LENTIVIRAL VECTORS, BY REGION,
2017–2024 (USD MILLION)
TABLE 16            GENE THERAPY MARKET FOR AAV VECTORS, BY REGION,
2017–2024 (USD MILLION)
TABLE 17            GENE THERAPY MARKET FOR OTHER VIRAL VECTORS, BY REGION,
2017–2024 (USD MILLION)
TABLE 18            GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 19            GENE THERAPY MARKET FOR NEUROLOGICAL DISEASES, BY REGION,
2017–2024 (USD MILLION)
TABLE 20            NUMBER OF CANCER PATIENTS, BY TYPE, 2012–2030
TABLE 21            GENE THERAPY MARKET FOR CANCER, BY REGION, 2017–2024 (USD MILLION)
TABLE 22            GENE THERAPY MARKET FOR HEPATOLOGICAL DISEASES, BY REGION,
2017–2024 (USD MILLION)
TABLE 23            GENE THERAPY MARKET FOR DMD, BY REGION, 2017–2024 (USD MILLION)
TABLE 24            GENE THERAPY MARKET FOR OTHER INDICATIONS, BY REGION,
2017–2024 (USD MILLION)
TABLE 25            GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 26            IN VIVO GENE THERAPY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 27            EX VIVO GENE THERAPY MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 28            GENE THERAPY MARKET, BY REGION, 2017–2024 (USD MILLION)

TABLE 29            NORTH AMERICA: GENE THERAPY MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 30            NORTH AMERICA: GENE THERAPY MARKET, BY VECTOR,
2017–2024 (USD MILLION)
TABLE 31            NORTH AMERICA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 32            NORTH AMERICA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 33            NORTH AMERICA: RETROVIRAL VECTORS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 34            NORTH AMERICA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 35            NORTH AMERICA: GENE THERAPY MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 36            LIST OF GENE THERAPY PIPELINE CANDIDATES OF US-BASED COMPANIES
TABLE 37            US FDA GENE THERAPY PRODUCT APPROVALS
TABLE 38            US: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 39            US: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 40            US: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 41            US: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 42            US: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 43            US: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 44            CANADA: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 45            CANADA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 46            CANADA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 47            CANADA: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 48            CANADA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 49            CANADA: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 50            EUROPE: GENE THERAPY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 51            EUROPE: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 52            EUROPE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 53            EUROPE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 54            EUROPE: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 55            EUROPE: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 56            EUROPE: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 57            GERMANY: INCIDENCE OF HEMATOLOGIC CANCERS, BY TYPE, 2018 VS. 2025
TABLE 58            GERMANY: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 59            GERMANY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)

TABLE 60            GERMANY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 61            GERMANY: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 62            GERMANY: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 63            GERMANY: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 64            FRANCE: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 65            FRANCE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 66            FRANCE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 67            FRANCE: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 68            FRANCE: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 69            FRANCE: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 70            UK: INCIDENCE OF CANCERS, BY TYPE, 2018 VS. 2025
TABLE 71            UK: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 72            UK: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 73            UK: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 74            UK: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 75            UK: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 76            UK: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 77            ITALY: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 78            ITALY: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 79            ITALY: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 80            ITALY: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 81            ITALY: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 82            ITALY: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 83            SPAIN: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 84            SPAIN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 85            SPAIN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 86            SPAIN: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 87            SPAIN: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 88            SPAIN: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 89            ROE: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 90            ROE: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 91            ROE: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)

TABLE 92            ROE: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 93            ROE: GENE THERAPY MARKET, BY DELIVERY METHOD, 2017–2024 (USD MILLION)
TABLE 94            ROE: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 95            ASIA PACIFIC: GENE THERAPY MARKET, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 96            ASIA PACIFIC: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 97            ASIA PACIFIC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 98            ASIA PACIFIC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 99            ASIA PACIFIC: RETROVIRAL VECTORS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 100          ASIA PACIFIC: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 101          ASIA PACIFIC: GENE THERAPY MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 102          JAPAN: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 103          JAPAN: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 104          JAPAN: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 105          JAPAN: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 106          JAPAN: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 107          JAPAN: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 108          CHINA: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 109          CHINA: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 110          CHINA: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 111          CHINA: RETROVIRAL VECTORS MARKET, BY TYPE, 2017–2024 (USD MILLION)
TABLE 112          CHINA: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 113          CHINA: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 114          REST OF APAC: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 115          REST OF APAC: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 116          REST OF APAC: GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)
TABLE 117          REST OF APAC: RETROVIRAL VECTORS MARKET, BY TYPE,
2017–2024 (USD MILLION)
TABLE 118          REST OF APAC: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 119          REST OF APAC: GENE THERAPY MARKET, BY INDICATION,
2017–2024 (USD MILLION)
TABLE 120          ROW: GENE THERAPY MARKET, BY VECTOR, 2017–2024 (USD MILLION)
TABLE 121          ROW: GENE THERAPY MARKET FOR NON-VIRAL VECTORS, BY TYPE,
2017–2024 (USD MILLION)

TABLE 122          ROW: GENE THERAPY MARKET, BY DELIVERY METHOD,
2017–2024 (USD MILLION)
TABLE 123          ROW: GENE THERAPY MARKET, BY INDICATION, 2017–2024 (USD MILLION)
TABLE 124          PRODUCT APPROVALS, 2016–2019
TABLE 125          ACQUISITIONS, 2016–2019
TABLE 126          COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS, 2016–2019
TABLE 127          EXPANSIONS, 2016–2019

LIST OF FIGURES

FIGURE 1            RESEARCH DESIGN
FIGURE 2            BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION
FIGURE 3            DATA TRIANGULATION METHODOLOGY
FIGURE 4            GENE THERAPY MARKET, BY VECTOR, 2019 VS. 2024 (USD MILLION)
FIGURE 5            GENE THERAPY MARKET, BY DELIVERY METHOD, 2019 VS. 2024 (USD MILLION)
FIGURE 6            GENE THERAPY MARKET, BY INDICATION, 2019 VS. 2024 (USD MILLION)
FIGURE 7            GENE THERAPY MARKET: REGIONAL SNAPSHOT
FIGURE 8            HIGH INCIDENCE OF CANCER & OTHER TARGETED DISEASES TO DRIVE
MARKET GROWTH
FIGURE 9            NON-VIRAL VECTORS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF
THE NORTH AMERICAN GENE THERAPY MARKET IN 2018
FIGURE 10          COUNTRIES IN NORTH AMERICA TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
FIGURE 11          GENE THERAPY MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 12          NON-VIRAL VECTORS SEGMENT WILL CONTINUE TO DOMINATE
THE GENE THERAPY MARKET DURING THE FORECAST PERIOD
FIGURE 13          IN VIVO GENE THERAPY SEGMENT WILL CONTINUE TO DOMINATE
THE GENE THERAPY MARKET DURING THE FORECAST PERIOD
FIGURE 14          NORTH AMERICA: GENE THERAPY MARKET SNAPSHOT
FIGURE 15          KEY DEVELOPMENTS IN THE GENE THERAPY MARKET
FIGURE 16          GENE THERAPY MARKET SHARE ANALYSIS, 2018
FIGURE 17          VENDOR COMPARISON MATRIX: GENE THERAPY MARKET
FIGURE 18          BIOGEN: COMPANY SNAPSHOT
FIGURE 19          SAREPTA THERAPEUTICS: COMPANY SNAPSHOT
FIGURE 20          GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
FIGURE 21          AMGEN, INC.: COMPANY SNAPSHOT
FIGURE 22          NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 23          SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
FIGURE 24          ANGES, INC.: COMPANY SNAPSHOT
FIGURE 25          JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT

当レポートのプレスリリースは発行されておりません。